ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Other EventsItem 8.01.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| 99.1 | ADMA Biologics, Inc. Press Release, dated October 17, 2018. |
ADMA BIOLOGICS, INC. ExhibitEX-99.1 2 e617996_ex99-1.htm ADMA Biologics Receives PDUFA Date for RI-002 Resubmission of Biologics License Application (“BLA”) Reinforces the Company’s Commitment to Commercialize Novel Therapies for Immune Compromised Patients to Address Unmet Medical Needs RAMSEY,…To view the full exhibit click here
About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
